Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions.
Chronic total occlusion
Left ventricular ejection fraction
Percutanous coronary intervention
Journal
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
ISSN: 2090-911X
Titre abrégé: Egypt Heart J
Pays: Germany
ID NLM: 9106952
Informations de publication
Date de publication:
24 May 2020
24 May 2020
Historique:
received:
01
11
2019
accepted:
07
05
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
26
5
2020
Statut:
epublish
Résumé
The benefit and safety of percutaneous coronary intervention (PCI) to chronic total occlusions (CTO) in patients with low and mid-range left ventricular ejection fraction (LVEF) continue to be evidence limited. The aim of our study was to investigate the impact of LVEF in patients undergoing CTO PCI and to evaluate the mid-term clinical outcome of those with low and mid-range LVEF. We assessed the periprocedural and mid-term outcomes of 75 patients undergoing CTO PCIs according to pre-procedural LVEF: group (N), ≥ 50% (normal, nom.= 25); group (M), 40-49% (mid-range, nom.= 25); and group (L), < 40% (low, nom.= 25); within 6 months of follow-up. The prevalence of DM and chronic kidney disease (CKD) was significantly higher in low LVEF group (60%, p = 0.04 and 48%, p = 0.01 respectively). Apart from significantly lower contrast volume in patients with low LVEF (p = 0.04), there was no significant difference between the three groups regarding the procedural time, SYNTAX score and J-CTO score. We noticed similar procedural success in the three groups (88% vs. 84% vs. 76%, p = 0.521). LVEF category failed to predict procedural success (OR = 0.652, p = 0.268). There was a highly significant improvement in angina 6 months following intervention in normal LVEF group (p value < 0.001). Grade of dyspnea significantly improved 6 months following intervention in mid-range LVEF and low LVEF groups (p value = 0.04 and 0.031 respectively). There was no significant difference between the three groups regarding the reported MACCEs (12% vs. 16% vs. 28%, p = 0.268). CTO PCI represents an efficient and safe strategy in patients with low and mid-range LVEFs. Mid-term outcomes in these patients were significantly improved following successful CTO PCI, without higher risk of MACCE at 6 months follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
The benefit and safety of percutaneous coronary intervention (PCI) to chronic total occlusions (CTO) in patients with low and mid-range left ventricular ejection fraction (LVEF) continue to be evidence limited. The aim of our study was to investigate the impact of LVEF in patients undergoing CTO PCI and to evaluate the mid-term clinical outcome of those with low and mid-range LVEF. We assessed the periprocedural and mid-term outcomes of 75 patients undergoing CTO PCIs according to pre-procedural LVEF: group (N), ≥ 50% (normal, nom.= 25); group (M), 40-49% (mid-range, nom.= 25); and group (L), < 40% (low, nom.= 25); within 6 months of follow-up.
RESULTS
RESULTS
The prevalence of DM and chronic kidney disease (CKD) was significantly higher in low LVEF group (60%, p = 0.04 and 48%, p = 0.01 respectively). Apart from significantly lower contrast volume in patients with low LVEF (p = 0.04), there was no significant difference between the three groups regarding the procedural time, SYNTAX score and J-CTO score. We noticed similar procedural success in the three groups (88% vs. 84% vs. 76%, p = 0.521). LVEF category failed to predict procedural success (OR = 0.652, p = 0.268). There was a highly significant improvement in angina 6 months following intervention in normal LVEF group (p value < 0.001). Grade of dyspnea significantly improved 6 months following intervention in mid-range LVEF and low LVEF groups (p value = 0.04 and 0.031 respectively). There was no significant difference between the three groups regarding the reported MACCEs (12% vs. 16% vs. 28%, p = 0.268).
CONCLUSION
CONCLUSIONS
CTO PCI represents an efficient and safe strategy in patients with low and mid-range LVEFs. Mid-term outcomes in these patients were significantly improved following successful CTO PCI, without higher risk of MACCE at 6 months follow-up.
Identifiants
pubmed: 32449095
doi: 10.1186/s43044-020-00065-1
pii: 10.1186/s43044-020-00065-1
pmc: PMC7246267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Références
J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67
pubmed: 2698218
J Am Coll Cardiol. 2012 Feb 28;59(9):825-35
pubmed: 22361403
N Engl J Med. 1985 Apr 4;312(14):932-6
pubmed: 4038784
Circulation. 1976 Sep;54(3):522-3
pubmed: 947585
JACC Cardiovasc Interv. 2017 Nov 13;10(21):2158-2170
pubmed: 29055762
J Am Heart Assoc. 2016 Oct 11;5(10):
pubmed: 27729332
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
Am Heart J. 2010 Jul;160(1):179-87
pubmed: 20598990
JACC Cardiovasc Interv. 2015 Feb;8(2):245-253
pubmed: 25700746
J Cardiovasc Magn Reson. 2016 Nov 5;18(1):78
pubmed: 27814739
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
Clinics (Sao Paulo). 2013 Oct;68(10):1333-7
pubmed: 24212840
Circulation. 1996 Oct 1;94(7):1545-52
pubmed: 8840842
Int J Cardiol. 2015;187:90-6
pubmed: 25828320
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
JACC Cardiovasc Interv. 2017 May 8;10(9):866-875
pubmed: 28473108
JACC Cardiovasc Imaging. 2016 May;9(5):547-56
pubmed: 27085432
Catheter Cardiovasc Interv. 2011 Sep 1;78(3):337-43
pubmed: 21413136
EuroIntervention. 2012 May 15;8(1):139-45
pubmed: 22580257
Circulation. 1987 Jul;76(1):142-54
pubmed: 3109764
J Am Coll Cardiol. 2013 Jan 22;61(3):282-94
pubmed: 23265332
Eur Heart J. 2012 Mar;33(6):768-75
pubmed: 22240495
Int J Cardiol. 2012 Nov 1;161(1):31-8
pubmed: 21722979
Am J Cardiol. 2015 May 15;115(10):1367-75
pubmed: 25784515
JACC Cardiovasc Interv. 2016 Sep 12;9(17):1790-7
pubmed: 27609252
J Am Coll Cardiol. 2015 Jun 9;65(22):2388-400
pubmed: 26046732
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
JACC Cardiovasc Interv. 2011 Feb;4(2):213-21
pubmed: 21349461
J Am Coll Cardiol. 2014 Jul 22;64(3):235-43
pubmed: 25034057
Circ Arrhythm Electrophysiol. 2012 Feb;5(1):147-54
pubmed: 22205684
J Nucl Med. 2009 Feb;50(2):214-9
pubmed: 19164219